DE10108614A1 - Wasserlösliches Konzentrat eines stoffwechselbeeinflussenden Wirkstoffes - Google Patents
Wasserlösliches Konzentrat eines stoffwechselbeeinflussenden WirkstoffesInfo
- Publication number
- DE10108614A1 DE10108614A1 DE10108614A DE10108614A DE10108614A1 DE 10108614 A1 DE10108614 A1 DE 10108614A1 DE 10108614 A DE10108614 A DE 10108614A DE 10108614 A DE10108614 A DE 10108614A DE 10108614 A1 DE10108614 A1 DE 10108614A1
- Authority
- DE
- Germany
- Prior art keywords
- polysorbate
- concentrate
- tocopherol
- water
- solubilizer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 title claims abstract description 69
- 235000019136 lipoic acid Nutrition 0.000 title claims abstract description 14
- 229960002663 thioctic acid Drugs 0.000 title claims abstract description 14
- 239000002904 solvent Substances 0.000 title claims abstract description 10
- 239000004550 soluble concentrate Substances 0.000 title claims abstract description 4
- 229920000136 polysorbate Polymers 0.000 title claims description 18
- 235000020660 omega-3 fatty acid Nutrition 0.000 title claims description 13
- 229940012843 omega-3 fatty acid Drugs 0.000 title claims description 13
- 229950008882 polysorbate Drugs 0.000 title claims description 13
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 title claims description 9
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 title abstract 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 title description 25
- 229930003799 tocopherol Natural products 0.000 title description 3
- 239000011732 tocopherol Substances 0.000 title description 3
- 239000002537 cosmetic Substances 0.000 title description 2
- 239000003814 drug Substances 0.000 title description 2
- 235000010384 tocopherol Nutrition 0.000 title 1
- 229960001295 tocopherol Drugs 0.000 title 1
- 235000004835 α-tocopherol Nutrition 0.000 claims abstract description 37
- 229940087168 alpha tocopherol Drugs 0.000 claims abstract description 35
- 229960000984 tocofersolan Drugs 0.000 claims abstract description 35
- 239000002076 α-tocopherol Substances 0.000 claims abstract description 35
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 239000013543 active substance Substances 0.000 claims abstract 3
- 239000012141 concentrate Substances 0.000 claims description 65
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 17
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 17
- 229920000053 polysorbate 80 Polymers 0.000 claims description 17
- 229940068968 polysorbate 80 Drugs 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 15
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 15
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 15
- 229940068977 polysorbate 20 Drugs 0.000 claims description 14
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 13
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 5
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 4
- 229940042585 tocopherol acetate Drugs 0.000 claims description 4
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-M succinate(1-) Chemical compound OC(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-M 0.000 claims description 2
- LTVDFSLWFKLJDQ-DKGMKSHISA-N alpha-Tocopherolquinone Natural products CC(C)CCC[C@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O LTVDFSLWFKLJDQ-DKGMKSHISA-N 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 235000008504 concentrate Nutrition 0.000 description 59
- 229930003427 Vitamin E Natural products 0.000 description 12
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 12
- 229940046009 vitamin E Drugs 0.000 description 12
- 235000019165 vitamin E Nutrition 0.000 description 12
- 239000011709 vitamin E Substances 0.000 description 12
- 238000003756 stirring Methods 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229940068965 polysorbates Drugs 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000008240 homogeneous mixture Substances 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000000693 micelle Substances 0.000 description 4
- 239000006014 omega-3 oil Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000011785 micronutrient Substances 0.000 description 3
- 235000013369 micronutrients Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000009993 protective function Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 235000019149 tocopherols Nutrition 0.000 description 2
- 150000003669 ubiquinones Chemical class 0.000 description 2
- 150000003772 α-tocopherols Chemical class 0.000 description 2
- -1 α-tocopherols) Chemical class 0.000 description 2
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 231100000716 Acceptable daily intake Toxicity 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000012994 industrial processing Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 150000003611 tocopherol derivatives Chemical class 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
778 Gramm auf etwa 85 Grad Celsius erwärmtem Polysorbat 80 werden etwa 222 Gramm Coenzym Q10 hinzugeben und die dabei entstandene Mischung etwa 5 Minuten in der Wärme gerührt, bis sich ein homogenes, transparentes, zähflüssiges Konzentrat ergeben hat. Dieses Konzentrat wird nach Abkühlung auf etwa 40 Grad Celsius zunächst cremig fest und intransparent. Sobald es auf etwa 60 Grad Celsius erwärmt ist, ist es wieder zähflüssig und transparent und läßt sich mit etwa 40 Grad Celsius warmem Wasser nach kurzem Rühren beliebig verdünnen. Auf diese Weise erhält man ein Coenzym Q10-Konzentrat, von dem ein Kilogramm etwa 222 Gramm Coenzym Q10 enthält.
Claims (9)
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10108614A DE10108614B4 (de) | 2001-02-22 | 2001-02-22 | Wasserlösliches Konzentrat eines stoffwechselbeeinflussenden Wirkstoffes |
DE10164844A DE10164844B4 (de) | 2001-02-22 | 2001-02-22 | Tocopherol-Konzentrat |
EP04010510A EP1475083B1 (de) | 2001-02-11 | 2002-02-11 | Verfahren zur Herstellung eines Wirkstoffkonzentrats sowie Wirkstoffkonzentrat |
CA002436273A CA2436273A1 (en) | 2001-02-11 | 2002-02-11 | Method for producing an active ingredient concentrate, and an active ingredient concentrate |
ES02719799T ES2324400T3 (es) | 2001-02-11 | 2002-02-11 | Procedimiento para la produccion de un concentrado de isoflavonas. |
AT04010510T ATE381923T1 (de) | 2001-02-11 | 2002-02-11 | Verfahren zur herstellung eines wirkstoffkonzentrats sowie wirkstoffkonzentrat |
US10/470,749 US20040081670A1 (en) | 2001-02-11 | 2002-02-11 | Method for producing an active ingredient concentrate, and an active ingredient concentrate |
PCT/EP2002/001416 WO2002085328A2 (de) | 2001-02-11 | 2002-02-11 | Verfahren zur herstellung eines wirkstoffkonzentrats sowie wirkstoffkonzentrat |
EP02719799A EP1377273B1 (de) | 2001-02-11 | 2002-02-11 | Verfahren zur herstellung eines isoflavon-konzentrats |
EP05027278A EP1645267A3 (de) | 2001-02-11 | 2002-02-11 | Verfahren zur Herstellung eines Wirkstoffkonzentrats sowie Wirkstoffkonzentrat |
JP2002582902A JP2004531530A (ja) | 2001-02-11 | 2002-02-11 | 活性物質の濃縮物の製法および活性物質の濃縮物 |
DE50213362T DE50213362D1 (de) | 2001-02-11 | 2002-02-11 | Verfahren zur herstellung eines isoflavon-konzentrats |
AU2002250914A AU2002250914A1 (en) | 2001-02-11 | 2002-02-11 | Method for producing an active ingredient concentrate, and an active ingredient concentrate |
AT02719799T ATE425743T1 (de) | 2001-02-11 | 2002-02-11 | Verfahren zur herstellung eines isoflavon- konzentrats |
MXPA03007141A MXPA03007141A (es) | 2001-02-11 | 2002-02-11 | Procedimiento para la preparacion de un concentrado de ingredientes activos, y un concentrado de ingredientes activos. |
DE50211435T DE50211435D1 (de) | 2001-02-11 | 2002-02-11 | Verfahren zur Herstellung eines Wirkstoffkonzentrats sowie Wirkstoffkonzentrat |
HK05103936A HK1073994A1 (en) | 2001-02-11 | 2005-05-10 | Method for producing an active ingredient concentrate, and active ingredient concentrate |
JP2006115962A JP2006241167A (ja) | 2001-02-11 | 2006-04-19 | 活性物質の濃縮物の製法および活性物質の濃縮物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10108614A DE10108614B4 (de) | 2001-02-22 | 2001-02-22 | Wasserlösliches Konzentrat eines stoffwechselbeeinflussenden Wirkstoffes |
Publications (2)
Publication Number | Publication Date |
---|---|
DE10108614A1 true DE10108614A1 (de) | 2002-09-05 |
DE10108614B4 DE10108614B4 (de) | 2005-04-28 |
Family
ID=7675168
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE10108614A Expired - Lifetime DE10108614B4 (de) | 2001-02-11 | 2001-02-22 | Wasserlösliches Konzentrat eines stoffwechselbeeinflussenden Wirkstoffes |
DE10164844A Expired - Lifetime DE10164844B4 (de) | 2001-02-22 | 2001-02-22 | Tocopherol-Konzentrat |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE10164844A Expired - Lifetime DE10164844B4 (de) | 2001-02-22 | 2001-02-22 | Tocopherol-Konzentrat |
Country Status (1)
Country | Link |
---|---|
DE (2) | DE10108614B4 (de) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10306177A1 (de) * | 2003-02-13 | 2004-09-02 | Aquanova German Solubilisate Technologies (Agt) | Wirkstoffkonzentrate |
WO2005056506A1 (de) * | 2003-12-10 | 2005-06-23 | Aquanova German Solubilisate Technologies (Agt) Gmbh | Lutein-konzentrat |
WO2006010370A1 (de) * | 2004-07-22 | 2006-02-02 | Aquanova German Solubilisate Technologies (Agt) Gmbh | Solubilisate von ätherischen ölen und anderen stoffen |
EP1624855A2 (de) * | 2003-05-22 | 2006-02-15 | Lipocine, Inc. | Pharmazeutische zusammensetzungen und dosierformen zur verabreichung von hydrophoben arzneimitteln |
EP1698328A2 (de) * | 2001-11-30 | 2006-09-06 | AQUANOVA German Solubilisate Technologies (AGT) GmbH | Tocopherol-Konzentrat |
DE102005032352A1 (de) * | 2005-07-08 | 2007-01-11 | Aquanova German Solubilisate Technologies (Agt) Gmbh | Solubilisate pfanzlicher Wirkstoffe sowie Verfahren zur Herstellung der Solubilisate |
US9205057B2 (en) | 2010-11-30 | 2015-12-08 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9757389B2 (en) | 2014-08-28 | 2017-09-12 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
US10561615B2 (en) | 2010-12-10 | 2020-02-18 | Lipocine Inc. | Testosterone undecanoate compositions |
US11052096B2 (en) | 2009-01-08 | 2021-07-06 | Lipocine Inc. | Steroidal compositions |
US11433083B2 (en) | 2010-11-30 | 2022-09-06 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US11559530B2 (en) | 2016-11-28 | 2023-01-24 | Lipocine Inc. | Oral testosterone undecanoate therapy |
US11707467B2 (en) | 2014-08-28 | 2023-07-25 | Lipocine Inc. | (17-ß)-3-oxoandrost-4-en-17YL tridecanoate compositions and methods of their preparation and use |
US12150945B2 (en) | 2018-07-20 | 2024-11-26 | Lipocine Inc. | Liver disease |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102012103767A1 (de) * | 2012-04-27 | 2013-10-31 | Chemische Fabrik Budenheim Kg | Antimikrobielles Mittel |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04300830A (ja) * | 1991-03-28 | 1992-10-23 | Zeria Pharmaceut Co Ltd | ビタミンe類の水溶液の製剤 |
GB9405041D0 (en) * | 1994-03-15 | 1994-04-27 | Smithkline Beecham Plc | Novel process |
TW371619B (en) * | 1996-10-07 | 1999-10-11 | Dsm Ip Assets Bv | Vitamin preparations for beverage applications |
DE10104847B4 (de) * | 2000-06-09 | 2006-12-21 | Aquanova German Solubilisate Technologies (Agt) Gmbh | Tocopherol-Konzentrat und Verfahren zu seiner Herstellung |
-
2001
- 2001-02-22 DE DE10108614A patent/DE10108614B4/de not_active Expired - Lifetime
- 2001-02-22 DE DE10164844A patent/DE10164844B4/de not_active Expired - Lifetime
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1698328A2 (de) * | 2001-11-30 | 2006-09-06 | AQUANOVA German Solubilisate Technologies (AGT) GmbH | Tocopherol-Konzentrat |
EP1698328A3 (de) * | 2001-11-30 | 2007-05-23 | AQUANOVA German Solubilisate Technologies (AGT) GmbH | Tocopherol-Konzentrat |
DE10306177A1 (de) * | 2003-02-13 | 2004-09-02 | Aquanova German Solubilisate Technologies (Agt) | Wirkstoffkonzentrate |
EP1624855A2 (de) * | 2003-05-22 | 2006-02-15 | Lipocine, Inc. | Pharmazeutische zusammensetzungen und dosierformen zur verabreichung von hydrophoben arzneimitteln |
EP1624855A4 (de) * | 2003-05-22 | 2010-05-19 | Lipocine Inc | Pharmazeutische zusammensetzungen und dosierformen zur verabreichung von hydrophoben arzneimitteln |
WO2005056506A1 (de) * | 2003-12-10 | 2005-06-23 | Aquanova German Solubilisate Technologies (Agt) Gmbh | Lutein-konzentrat |
WO2006010370A1 (de) * | 2004-07-22 | 2006-02-02 | Aquanova German Solubilisate Technologies (Agt) Gmbh | Solubilisate von ätherischen ölen und anderen stoffen |
US8377494B2 (en) | 2004-07-22 | 2013-02-19 | Aquanova Ag | Concentrates of active agents, such as W-3 fatty acids, and polysorbate |
DE102005032352A1 (de) * | 2005-07-08 | 2007-01-11 | Aquanova German Solubilisate Technologies (Agt) Gmbh | Solubilisate pfanzlicher Wirkstoffe sowie Verfahren zur Herstellung der Solubilisate |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
US11052096B2 (en) | 2009-01-08 | 2021-07-06 | Lipocine Inc. | Steroidal compositions |
US10226473B2 (en) | 2010-11-30 | 2019-03-12 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US11364250B2 (en) | 2010-11-30 | 2022-06-21 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9757390B2 (en) | 2010-11-30 | 2017-09-12 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9943527B2 (en) | 2010-11-30 | 2018-04-17 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9949985B2 (en) | 2010-11-30 | 2018-04-24 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US11433083B2 (en) | 2010-11-30 | 2022-09-06 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US10973833B2 (en) | 2010-11-30 | 2021-04-13 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9480690B2 (en) | 2010-11-30 | 2016-11-01 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US10881671B2 (en) | 2010-11-30 | 2021-01-05 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US11364249B2 (en) | 2010-11-30 | 2022-06-21 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US10799513B2 (en) | 2010-11-30 | 2020-10-13 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US10716794B2 (en) | 2010-11-30 | 2020-07-21 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9205057B2 (en) | 2010-11-30 | 2015-12-08 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US11311555B2 (en) | 2010-11-30 | 2022-04-26 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US10561615B2 (en) | 2010-12-10 | 2020-02-18 | Lipocine Inc. | Testosterone undecanoate compositions |
US9757389B2 (en) | 2014-08-28 | 2017-09-12 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
US11298365B2 (en) | 2014-08-28 | 2022-04-12 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
US11707467B2 (en) | 2014-08-28 | 2023-07-25 | Lipocine Inc. | (17-ß)-3-oxoandrost-4-en-17YL tridecanoate compositions and methods of their preparation and use |
US11872235B1 (en) | 2014-08-28 | 2024-01-16 | Lipocine Inc. | Bioavailable solid state (17-β)-Hydroxy-4-Androsten-3-one esters |
US12171770B1 (en) | 2014-08-28 | 2024-12-24 | Lipocine Inc. | Bioavailable solid state (17-beta)-hydroxy-4-androsten-3-one esters |
US11559530B2 (en) | 2016-11-28 | 2023-01-24 | Lipocine Inc. | Oral testosterone undecanoate therapy |
US12150945B2 (en) | 2018-07-20 | 2024-11-26 | Lipocine Inc. | Liver disease |
Also Published As
Publication number | Publication date |
---|---|
DE10164844B4 (de) | 2005-05-25 |
DE10108614B4 (de) | 2005-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1475083B1 (de) | Verfahren zur Herstellung eines Wirkstoffkonzentrats sowie Wirkstoffkonzentrat | |
DE10108614A1 (de) | Wasserlösliches Konzentrat eines stoffwechselbeeinflussenden Wirkstoffes | |
EP1404291B1 (de) | Wasserfreies ubichinon-konzentrat | |
EP0551638B1 (de) | Stabile, flüssige Präparate fettlöslicher Substanzen | |
DE3926658C2 (de) | Fettsäurezusammensetzung | |
EP1338271B1 (de) | Wässrige Lösung von Ascorbinsäure | |
DE3138088C2 (de) | ||
DE60111362T2 (de) | Stabilisierte ascorbinsäure-lösungen | |
EP0866117A1 (de) | Mikroemulsion | |
EP1516662A1 (de) | Zubereitung bestehend aus mindestens zwei Nanoemulsionen | |
EP0152106A2 (de) | Rheumamittel | |
EP2066310B1 (de) | Emulsionen enthaltend gummi arabicum | |
WO1992020241A1 (de) | Nährstoffzubereitung | |
DE10104847B4 (de) | Tocopherol-Konzentrat und Verfahren zu seiner Herstellung | |
EP0366156B1 (de) | Mittel zur Behandlung von Erkrankungen der Venen und des Analbereichs | |
EP3473240B1 (de) | Eine im wesentlichen wasserfreie zusammensetzung, insbesondere zur verwendung als nahrungsergänzungsmittel | |
EP1781119B1 (de) | Liponsäure-konzentrat | |
DE1617309C3 (de) | Verfahren zur Herstellung von pharmazeutischen Präparaten mit Vitamingehalt | |
EP2142015A2 (de) | Emulsionsvorkonzentrate sowie micellare formulierungen enthaltend wurzelharz | |
DE102004051245A1 (de) | Vitamin C-Solubilisat | |
DE102017009186A1 (de) | Lutein und -derivate enthaltende Zusammensetzung sowie Verfahren zur Herstellung | |
DE225644C (de) | ||
DE10109708A1 (de) | Wasserlösliches Wirkstoffkonzentrat | |
EP0141051A2 (de) | Weichgelatinekapseln enthaltend Vitamin A und E | |
DE102010021688A1 (de) | Verfahren zur Herstellung eines micellaren Wirkstoffkonzentrats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8110 | Request for examination paragraph 44 | ||
8172 | Supplementary division/partition in: |
Ref document number: 10164844 Country of ref document: DE Kind code of ref document: P |
|
Q171 | Divided out to: |
Ref document number: 10164844 Country of ref document: DE Kind code of ref document: P |
|
8127 | New person/name/address of the applicant |
Owner name: AQUANOVA GERMAN SOLUBILISATE TECHNOLOGIES (AGT) GM |
|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: AQUANOVA AG, 64295 DARMSTADT, DE |
|
R082 | Change of representative |
Representative=s name: BLUMBACH ZINNGREBE, DE Representative=s name: BLUMBACH ZINNGREBE PATENT- UND RECHTSANWAELTE , DE |
|
R082 | Change of representative |
Representative=s name: AUGSPURGER - TESCH - FRIDERICHS PATENT- UND RE, DE |
|
R071 | Expiry of right |